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Background: Quality of life (QoL) is an important component in the evaluation of the well-being 
of people living with HIV and AIDS (PLWHA), especially with the appreciable rise in longevity of 
PLWHA. The analysis of the quality of life is essential for the healthcare policies and services 
directed toward PLWHA, since this indicator values the perception of people about their own life 
and health. However, little is known about the determinant of QoL in PLWHA in Papua. The aim of 
this study was to analyze survival predictors of people living with HIV/ AIDS in Wamena, Papua, 
Indonesia. 
Subjects and Method: This was a retrospective cohort study conducted in Wamena Hospital, 
Papua, from December 2017 to February 2018. A cohort of 304 PLWHA was selected for this study 
from the medical record at Wamena Hospital. The dependent variable was survival. The 
independent variables were adherence to ART, nutritional status, age, and coinfection. The data 
were collected from medical record and questionnaire. The data were analyzed by Cox regression 
model. 
Results: The risk of dying of PLWHA if adherent to take the ART was lower than not adherent to 
take the ART (HR=0.45; 95% CI= 0.06 to 0.33; p= 0.002).The risk of dying of PLWHA with poor 
nutritional status was higher than good nutritional status (HR= 12.78; 95% CI= 6.81 to 23.98; p< 
0.001). The risk of dying of PLWHA aged ≥35 years was slightly higher than <35 years (HR= 1.47; 
95% CI= 1.00 to 2.17; p= 0.050). The risk of dying of PLWHA with coinfected was higher than 
without coinfected (HR= 1.59; 95% CI= 1.15 to 2.23; p= 0.006). 
Conclusion: The risk of dying of PLWHA decreases if adherent to take the ART, but increases 
with poor nutritional status, age ≥35 years, and coinfection. 
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BACKGROUND 
Epidemiology of AIDS in Indonesia has lasted 
20 years and the impact is not easy to 
overcome. According to the Indonesia 
Ministry of Health, the total number of HIV 
cases since 2005-2016 was 208,920 cases, in 
2016 the total cases reached 17,847. while 
AIDS cases accounted for 11,807 cases. 
(Kemenkes RI, 2016). 
The provincial government of Papua 
has reported a total of 22,429 HIV cases and 
13,335 AIDS cases from 2005 to 2016 with 
1,570 new cases. (Kemenkes RI, 2016)  
Wamena District Hospital has reported 
the cumulative number of people who have 
been admitted to HIV treatment until April 
2017 as many as 5304 people where only 730 
people are screened for tuberculosis coinfec-
tion and 582 people are infected with TB. In 
addition, 388 people died until the end of 
April 2017.  
There is no cure for HIV infection that 
has been found until now and there is no 
vaccine available for prevention, the infected 
person should take antiretroviral therapy for 
life, but this drug only can slow the progress-
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ion of the virus in the early stages. Even if 
they can survive, people living with HIV/ 
AIDS (PLWHA) may not live well or feel 
satisfied. Quality of life becomes important to 
identify the condition of PLWHA in living its 
life. (Hasanah et al., 2011; Arjun et al., 2015). 
HIV/AIDS prevention program in 
Indonesia leading to the paradigm of zero 
new infection, zero AIDS-related death, and 
zero discrimination. These Paradigm were 
trying to be realized in four pillars, namely (1) 
Prevention of HIV transmission. (2) Care, 
support, and treatment (PDP). (3) Mitigation 
of impacts of psychosocial-economic support. 
(4) Creation of a conducive environment.  
The second pillar of Care, Support, and 
Treatment (CST) efforts include strengthen-
ing and developing health services, prevent-
ing and treating opportunistic infections, 
antiretroviral treatment, support education, 
and training for PLW.  
The program aims to reduce morbidity 
and hospitalization rates, AIDS-related 
mortality rates, and improve the quality of life 
of HIV-infected persons at various stages. 
(Kementerian Kesehatan Republik Indonesia 
- Direktorat Jenderal Pengendalian Penyakit 
dan Penyehatan Lingkungan, 2011). 
The aim of this study was to analyze 
survival predictors of people living with HIV/ 
AIDS in Wamena, Papua, Indonesia.  
 
SUBJECTS AND METHOD 
This was a retrospective cohort study 
conducted in Wamena Hospital, Papua, from 
December 2017 to February 2018.  
A cohort of 304 PLWHA was selected 
for this study from the medical record at 
Wamena Hospital. The dependent variable 
was survival. The independent variables were 
adherence to ART, nutritional status, age, and 
coinfection.  
Survival was defined as the length of 
time required by the patient since the 
diagnosis of PLWHA to death. 
Survival assessment for surviving 
patients is the length of the patient suffering 
from AIDS until the study is completed with a 
permanent status of life. 
Co-infection is a coexisting disease 
experienced after a patient has AIDS, in other 
words, is a disease that arises as a result of 
AIDS include tuberculosis, sexually trans-
mitted diseases, non-sexual infectious 
diseases, diarrhea, and other chronic diseases 
The data were collected from medical 
record and questionnaire. The data were 
analyzed by Cox regression model.  
 
RESULTS 
The risk of dying of PLWHA if adherent to 
take the ART was lower than not adherent to 
take the ART (HR=0.45; 95% CI= 0.06 to 
0.33; p= 0.002). 
The risk of dying of PLWHA with poor 
nutritional status was higher than good 
nutritional status (HR= 12.78; 95% CI= 6.81 
to 23.98; p< 0.001).  
The risk of dying of PLWHA aged ≥35 
years was slightly higher than <35 years 
(HR= 1.47; 95% CI= 1.00 to 2.17; p= 0.050). 
The risk of dying of PLWHA with coinfected 
was higher than without coinfected (HR= 
1.59; 95% CI= 1.15 to 2.23; p= 0.006). 
Table 1. The results cox regression analysis of survival predictor of PLWHA 
Independent Variables HR 
95% CI 
p 
Lower limit Upper limit 
Adherent to take the ART 0.45 0.06 0.33    0.002 
Poor nutritional status 12.78 6.81 23.98 <0.001 
Aged ≥35 years 1.47 1.00 2.17    0.050 
Coinfected 1.59 1.15 2.23    0.006 
N observation = 184     
Log likelihood = -84.53     
p<0.001     
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Figure 1. Kaplan-Meier Survival estimates 
 
DISCUSSIONS 
1. Adherent to ART 
The development of antiretroviral drugs 
has significantly altered the perception of 
HIV / AIDS from a very potentially fatal 
illness to be chronic and potentially treat-
able, and the availability the administration 
of antiretroviral therapy (ART) has signifi-
cantly reduced HIV and AIDS-related 
mortality and morbidity. (Oguntibeju, 
2012) 
This situation makes the World 
Health Organization (WHO) strive to 
achieve the 90% coverage target of care for 
all HIV patients as well as 90% virological 
success in treated patients  and requires a 
minimum achievement of adherence appro-
ximately 95% (UNAIDS,2015; Paterson et 
al., 2000). 
According to(Iacob and Jugulete, 
2017) here are 4 main factors that can affect 
ART adherence: (1) Selective antiretroviral 
drugs, which can cause various side effects. 
(2) Doctors' devotions include lack of time 
dedicated to counseling and building trust 
relationships. (3) Patients have not been 
able to receive the benefits and disadvan-
tages of ART. (4) social and family back-
grounds can not persuade patients to 
continue ART. 
Effective antiretroviral therapy can 
decrease morbidity and mortality for people 
with a CD4 cell count of 200-350 cells / 
mm3. Various data indicate that decreased 
risk of mortality and complication related 
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AIDS or non-AIDS in PLWHA who started 
ART when CD4 cell counts, 350 cells / μL. 
(Schey., et al  2016).  
In 2010, HIV-1 treatment guidelines 
in the United States and the EU recommen-
ded three fully active antiretroviral drugs 
when CD4 + cell in peripheral blood 
decreased to 350 cells / mm3, a stage where 
viral rates could often reach 10,000-
100,000 copies per mL.. (Arts and Hazuda, 
2012; Lodi et al., 2011) 
The Kaplan-Meier survival estimated 
of patients who adherent to antiretroviral 
therapy is much higher than non-adherent 
patients. 
ART provides an effective treatment 
for patients with 6 classes of pharma-
cological drugs including: (1) Nucleoside 
reverse transcriptase inhibitors (NRTIs). 
(2) Non-nucleoside reverse transcriptase 
inhibitors (NNRTIs). (3) Protease inhibit-
ors (PIs). (4) Integrase inhibitor (INSTIs). 
(5) Fusion Inhibitor (FI). (6) Chemokine 
receptor antagonist (CCR5 antagonist). (7) 
Inhibitor entry (post-mounted inhibitor 
directed to CD4). (Rathbun, 2017). 
Each class targets different steps in 
the viral life cycle and its use in clinical 
practice was largely determined by ease or 
complexity of use, side effects, clinical 
efficacy, practice guidance, and physician 
preferences. Non-compliance causes a 
failure of therapy and the occurrence of 
resistance mechanisms.      
NRTIs were managed as prodrugs 
requiring host cell entry and phosphory-
lation by cellular kinase before providing 
antiviral effects. NRTIs prevent the forma-
tion of 30-50-phosphodiester bonds result-
ing in termination of growth and 
termination of viral DNA chains. (Boyer et 
al., 2001; Rigourd et al., 2002). 
Resistance to NRTIs was mediated by 
two mechanisms: ATP-dependent pyro-
phosphorolysis which is the removal of 
NRTIs from the 30 ends of the newborn 
chains and increased discrimination 
between the deoxyribonucleotide substrate 
and the inhibitor. (Naeger., et al 2002). 
NNRTI inhibits HIV-1 by binding and 
promoting the formation of proximal 
hydrophobic pockets. NNRTI binding to the 
virus may reduce polymerase activity. 
(Sluis-Cremer., et al 2004). 
NNRTI resistance was generated from 
substitutions of amino acids such as L100, 
K101, K103, E138, V179, Y181, and Y188 in 
NNRTI binding sacs.. (Bacheler et al., 
2000; Dykes et al., 2001). 
The HIV-1 Protease is an enzyme 
responsible for the cleavage of viral gags 
and polyprotein precursor gags during 
virion maturation. However, protease genes 
have great plasticity, with polymorphism 
observed in 49 of 99 codons, and many 
more than 20 substitutions known to be 
associated with resistance (Shafer et al., 
2007). 
The HIV-1 entry exploits some host 
proteins for a set of complicated events 
leading to the fusion membrane and the 
release of the viral nucleus into the 
cytoplasm. Fusion Inhibitor is a crystalline 
structure of ectodomain gp41 and from 
ectodomain partnered with peptide inhi-
bitors (C34). The fusion inhibitor peptide 
was  designed based on the discovery that 
two homologous domains in the gp41 virus 
protein must interact, one of these domains 
by heterologous proteins can bind and 
interfere with intramolecular interactions 
of viral proteins and have significant 
antiviral activity against HIV-1 (Lalezari et 
al., 2003; Wilen., et al 2012). 
The CCR5 antagonist is a small 
molecule bonded to the hydrophobic pouch 
inside the CCR5 helical transmembrane 
that has been shown to inhibit viral 
replication in the macaque model and to 
prevent vaginal transmission. So far, three 
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antagonists (VCV, MVC, and Aplaviroc) 
have been shown to inhibit human 
replication virus. (Dorr et al., 2005; Veazey 
et al., 2005). 
2. Nutritional status 
According to WHO, nutritional support 
should be fundamental for a comprehensive 
response to HIV and AIDS. Malnutrition 
status in PLWHA were associated with 
chronic complication, increased morbidity, 
and reduced survival, even when ART is 
available (Who and Searo, 2008; Arjun et 
al., 2015). 
A study in the United States found 
that micronutrient supplements significant-
ly increased CD4 cell counts, and studies 
among HIV-infected adults in Haiti, Kenya, 
Malawi, and Zambia have shown significant 
positive effects of micronutrient supple-
mentation. Increased intake of either macro 
or micronutrient food can optimize health 
outcomes for people living with HIV. 
(Kaiser et al., 2006). 
A previous study from (Venter., et al 
2009) showed the correlation between CD4 
cell count, body weight, and body mass 
index (BMI).  when CD4 number decrease 
by 100 cells / μl was associated with a 1.9 kg 
decrease in body weight of HIV-infected 
adults. 
Diarrhea and fever were clinical 
complications associated with chronic 
malnutrition and weight loss. The impact of 
HIV/AIDS can decline dramatically if 
individuals take care of their health, plan 
for the future for their families and prevent 
further spread of infection Patients need to 
get educational nutrition on topics such as 
diet diversity, food safety principles and 
recommendations set for the community 
including food aid targeted.(Kirkcaldy et 
al., 2006; Hendricks et al., 2010). 
Health workers should provide edu-
cation and build nutrition support groups 
for PLWHA. 
3. Co-infection   
Co-infection is a major factor that promotes 
increased morbidity and mortality in 
PLWHA. The World Health Organization 
(WHO) reported that more or less a quarter 
of the 1.5 million deaths of HIV-infected 
patients were associated with tuberculosis 
and others co-infection (Lewandowski, 
2015) 
Based on the status of immune 
suppression in PLWHA, other co-infections 
can present with a variety of clinical 
syndromes with atypical manifestations 
that pose challenges in diagnosis and 
clinical management.. 
Chronic HIV co-infection is more than 
other infectious diseases, as the HIV virus 
immobilizes the immune system and allows 
reactivation of the active pathogens or 
increases susceptibility to exogenous patho-
gens. Although in the current era of morbi-
dity and mortality the opportunistic 
diseases have declined, infections such as 
Cytomegalovirus (CMV), tuberculosis, 
hepatitis C and B, Human Papillomavirus 
(HPV) remain a major health problem in 
chronically chronic HIV-infected indivi-
duals (Zanoni and Gandhi, 2014). 
The role of co-infection in increasing 
morbidity and mortality remains a major 
problem today. In a study of HIV-infected 
populations in South Africa, showed that 
patients with active TB infection had 
elevated levels of soluble inflammatory bio-
markers associated with monocyte acti-
vation, as well as T-cell activation surface 
markers (Sullivan et al., 2015)   
Patients with active TB infection had 
lower CD4 T-cells. this explains that Co-
Infection plays a fundamental role in 
immune activation in all stages of coinfect-
ed HIV infection may increase the risk of 
higher cardiovascular disease (Boulougoura 
and Sereti, 2016).  
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